Efficacy of reulgolix in controlled ovarian stimulation cycles

Efficacy of reulgolix in controlled ovarian stimulation cycles - Efficacy of reulgolix in controlled ovarian stimulation cycles

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000045607

Enrollment

1000

Registered

2021-09-29

Start date

2019-01-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility

Interventions

cetrorelix acetate (Cetrotide

Merck Biopharma Co., Ltd., Tokyo, Japan) 0.25 mg/day or ganirelix acetate (GANIREST

MSD KK a subsidiary of Merck &amp

Co. Inc., Kenilworth, NJ, USA) 0.25 mg/day 40 mg/day of relugolix (RELUMINA

ASKA Pharmaceutical Co., Ltd., Tokyo, Japan)

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1) patients who were scheduled for oocyte retrieval at our clinic and planned to undergo a COS cycle with an antagonist or natural protocols, and 2) patients who could provide written consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
The number of retrieved oocytes.	—

Secondary

Measure	Time frame
The number of mature oocytes (metaphase II). The number of cleavage stage embryos (Veeck's classification 1 to 3) The detail of adverse-event	—

Countries

Japan

Contacts

Public ContactShinnosuke Komiya

HORAC Grand Front Osaka Clinic Gynecology

komiya520@ivfjapan.com+81663778824

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026